登陆
当前位置: 首页 >> 检索结果

结果排序

文献格式

出版时间

出版类型

出版语言
共有 4693 条符合本次的查询结果， 用时 4.5307105 秒

3641. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.

作者: Catherine M Broome.;Vickie McDonald.;Yoshitaka Miyakawa.;Monica Carpenedo.;David J Kuter.;Hanny Al-Samkari.;James B Bussel.;Marie Godar.;Jaume Ayguasanosa.;Kristof De Beuf.;Francesco Rodeghiero.;Marc Michel.;Adrian Newland.; .
来源: Lancet. 2023年402卷10413期1648-1659页
Primary immune thrombocytopenia is an autoimmune disorder mediated partly by platelet autoantibodies, resulting in thrombocytopenia, bleeding, and constitutional symptoms. Efgartigimod, a first-in-class novel human IgG1 Fc fragment, binds the neonatal Fc receptor with high affinity and thus reduces serum IgG concentrations, including autoantibodies. The objective of this study was to evaluate the efficacy and safety of efgartigimod in adults with persistent and chronic primary immune thrombocytopenia.

3642. Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.

作者: Syed Mahamad.;Donald M Arnold.
来源: Lancet. 2023年402卷10413期1599-1601页

3643. COVAX: the unspent billions.

作者: Ann Danaiya Usher.
来源: Lancet. 2023年402卷10408期1119-1122页

3644. Pulmonary embolism with thrombus-in-transit across a patent foramen ovale.

作者: John W Ostrominski.;Christine J Wang.;Umberto Campia.;Jean M Connors.;Dirk J Varelmann.;Domagoj Mladinov.;Mohamed Keshk.;Hicham Skali.
来源: Lancet. 2023年402卷10408期1170页

3645. Department of Error.

来源: Lancet. 2023年402卷10408期1132页

3646. Department of Error.

来源: Lancet. 2023年402卷10408期1132页

3647. COVID toes, newborn blue toes, and prepartum SARS-CoV-2 infection - Authors' reply.

作者: Christoph Hochmayr.;Ursula Kiechl-Kohlendorfer.;Elke Griesmaier.
来源: Lancet. 2023年402卷10408期1132页

3648. Department of Error.

来源: Lancet. 2023年402卷10408期1132页

3649. Natural SARS-CoV-2 infection-induced immune protection against re-infection.

作者: Claude Matuchansky.
来源: Lancet. 2023年402卷10408期1131页

3650. COVID toes, newborn blue toes, and prepartum SARS-CoV-2 infection.

作者: Ya Bin Zhou.;Zi Gang Xu.
来源: Lancet. 2023年402卷10408期1131-1132页

3651. Cautionary notes on the COVID-19 re-infection study.

作者: Zhi Qu.
来源: Lancet. 2023年402卷10408期1130-1131页

3652. Extra data to confirm waning protection of omicron (B.1.1.529) natural immunity.

作者: Maria Elena Flacco.;Cecilia Acuti Martellucci.;Lamberto Manzoli.
来源: Lancet. 2023年402卷10408期1129页

3653. Overcoming COVID-19 vaccine hesitancy hurdles.

作者: Chengliang Yang.;Linda Lapp.;Scott J Tebbutt.
来源: Lancet. 2023年402卷10408期1129-1130页

3654. Striving to afford free health care in Greece during COVID-19.

作者: Christos Tsagkaris.;Andreas S Papazoglou.;Dimitrios V Moysidis.;Stavros P Papadakos.;Marios Papadakis.
来源: Lancet. 2023年402卷10408期1128-1129页

3655. Community COVID-19 response in WHO's European region.

作者: Leonardo Palumbo.;Camila A Picchio.;Catherine Smallwood.;Cristiana Salvi.;Gerald Rockenschaub.
来源: Lancet. 2023年402卷10408期1127页

3656. Arcturus (XBB.1.16) COVID-19 subvariant emergence in Indonesia.

作者: Tungki Pratama Umar.
来源: Lancet. 2023年402卷10408期1127-1128页

3657. Offline: We have a decade.

作者: Richard Horton.
来源: Lancet. 2023年402卷10408期1118页

3658. Immigration reform in the USA: health must come first.

作者: The Lancet.
来源: Lancet. 2023年402卷10408期1107页

3659. Morocco earthquake: mitigating the impact on patients with cancer.

作者: Khalid El Bairi.;Ouissam Al Jarroudi.;Said Afqir.
来源: Lancet. 2023年402卷10410期1323-1324页

3660. The transformative potential of law for gender and cancer.

作者: Sondra Davoren.;Suzanne Zhou.;Evita Ricafort.;Daiana Buresova.;Andrea Lucas.;Tarishi Desai.;Hayley Jones.
来源: Lancet. 2023年402卷10417期2051-2053页
共有 4693 条符合本次的查询结果， 用时 4.5307105 秒